- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Antipsychotic Drug Fights Leukemia in Model
Strategies that identify new uses for existing drugs have grown in popularity in recent years as a way of quickly developing new disease therapies. Zebrafish models are cost-effective platforms for rapidly conducting drug screens as well as basic stem cell, genetic, cancer and developmental research.
The study provides a prime example of finding new uses for older drugs. The findings also suggest that developing drugs that activate PP2A while avoiding perphenazine's psychotropic effects could help clinicians make much-needed headway against T-cell ALL and perhaps other tumors as well.
T-cell ALL, or T-ALL, is rarer and more aggressive than the B-cell form of ALL and has a relatively poor prognosis. Despite improvements in the treatments available, 20% of children and more than 50%of adults diagnosed with T-ALL succumb to it.
Read the full story here: http://bit.ly/1arLGU3
Source: Drug Discovery and Development
A 50-year-old antipsychotic drug can combat a difficult-to-treat form of acute lymphoblastic leukemia (ALL) in zebrafish, according to new a study led by Harvard Medical School researchers. The drug, perphenazine, works by turning on a cancer-suppressing enzyme called PP2A and causing malignant tumor cells to self-destruct.
Zanubrutinib Plus Obinutuzumab Granted Accelerated FDA Approval for R/R Follicular Lymphoma
March 7th 2024The FDA granted accelerated approval to combination zanubrutinib and obinutuzumab for the treatment of relapsed or refractory (R/R) follicular lymphoma following 2 or more lines of therapy.
Read More
Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity
February 3rd 2022On this episode of Managed Care Cast, we speak with Meghan Gutierrez, CEO of the Lymphoma Research Foundation, about financial toxicity, how the pandemic has affected patients’ financial needs when they have cancer, health care disparities and care gaps, and more.
Listen
ICYMI: Highlights From ASH 2023
December 20th 2023The most-read content from the 2023 American Society of Hematology Annual Meeting and Exposition included the latest in treating hematologic malignancies, the hope brought by novel therapy strategies, and the potential for artificial intelligence to improve diagnostic accuracy.
Read More
Keeping Patients With Cancer Out of the ED Through Dedicated Urgent Care
October 13th 2021On this episode of Managed Care Cast, we bring you an interview conducted by the editorial director of OncLive® who talks with the advance practice provider chief at Winship Cancer Institute about how having a dedicated cancer urgent care center will make cancer treatment plans seamless whil helping patients avoid exposure to infectious diseases in emergency department waiting rooms.
Listen
